Clinical Research Directory
Browse clinical research sites, groups, and studies.
Propionic Acid in Multiple Sclerosis
Sponsor: Salzburger Landeskliniken
Summary
The purpose of this study is to demonstrate the superiority of propionic acid over placebo as add on treatment in multiple sclerosis (MS).
Official title: Propionic Acid in Multiple Sclerosis - a Placebo-controlled Randomized Double-blinded Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
101
Start Date
2024-05-01
Completion Date
2024-10-09
Last Updated
2026-09-15
Healthy Volunteers
No
Conditions
Interventions
Propionic acid 1000 mg capsule
Patients will be assigned to propionic acid or placebo as add on MS treatment.
Placebo
Patients will be assigned to propionic acid or placebo as add on MS treatment.
Locations (1)
Salzburger Landeskliniken
Salzburg, State of Salzburg, Austria